Expert Review of Hematology最新文献

Reassuring clinicians and patients using SGLT-2 inhibitors: is there a need to worry about blood complications? 让使用SGLT-2抑制剂的临床医生和患者放心：有必要担心血液并发症吗？

IF 2.1 4区医学

Expert Review of Hematology Pub Date : 2025-10-18 DOI: 10.1080/17474086.2025.2575047

Ji Yun Lee, Soo-Mee Bang

引用次数: 0

Updated guidelines in the treatment of myeloma bone disease in 2025: consensus statement by the Medical and Scientific advisory group of Australia (MSAG) to myeloma australia. 2025年骨髓瘤骨病治疗的最新指南：澳大利亚医学和科学咨询小组（MSAG）对澳大利亚骨髓瘤的共识声明。

IF 2.1 4区医学

Expert Review of Hematology Pub Date : 2025-10-13 DOI: 10.1080/17474086.2025.2574716

Angelina Yong, Kate Vandyke, Bradley Augustson, Georgia McCaughan, Dipti Talaulikar, Ferenc Szabo, Henry Miles Prince, Phoebe Joy Ho, Hang Quach, Simon J Harrison, Cindy Hs Lee

{"title":"Updated guidelines in the treatment of myeloma bone disease in 2025: consensus statement by the Medical and Scientific advisory group of Australia (MSAG) to myeloma australia.","authors":"Angelina Yong, Kate Vandyke, Bradley Augustson, Georgia McCaughan, Dipti Talaulikar, Ferenc Szabo, Henry Miles Prince, Phoebe Joy Ho, Hang Quach, Simon J Harrison, Cindy Hs Lee","doi":"10.1080/17474086.2025.2574716","DOIUrl":"https://doi.org/10.1080/17474086.2025.2574716","url":null,"abstract":"Introduction: Multiple myeloma is a hematological malignancy characterized by clonal plasma cells proliferation within the bone marrow, often resulting in osteolytic bone disease. Traditionally, bisphosphonates such as zoledronic acid and pamidronate, have been used in the prophylaxis and treatment of myeloma bone disease (MBD).Areas covered: A comprehensive, systematic review using these key words, 'multiple myeloma,' 'myeloma bone disease,' 'bisphosphonates,' 'denosumab,' 'osteonecrosis' was conducted on Medline and Cochrane databases from 1995 to 2024. Priority was given to randomized, double-blinded clinical trials; with inclusion oflarge case cohort studies in view of the limited comparison between different bone resorptive agents in the treatment of myeloma bone disease.Expert opinion: This updated guideline recommends a two-year course of bisphosphonates treatment, with suggested extension of dosing intervals if the disease remains stable.Denosumab, a monoclonal antibody targeting receptor activator of nuclear factor **B ligand (RANKL), has demonstrated efficacy and non-inferiority compared to zoledronic acid in the treatment of MBD and may serve as an alternative treatment option especially with renal impairment. Further research into the utility of bone turnover markers for guiding anti-resorptive therapy in myeloma bone disease may provide significant clinical benefit. In addition, therapeutic strategies aimed at enhancing osteoblastic activity represent a potential therapeutic strategy.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145279363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

May obesity increase the risk of lymphoma? Insights from genetic evidence. 肥胖会增加患淋巴瘤的风险吗？来自基因证据的见解。

IF 2.1 4区医学

Expert Review of Hematology Pub Date : 2025-10-13 DOI: 10.1080/17474086.2025.2570329

Jing Liu, Jun Wang, Yuanyuan Zhang

{"title":"May obesity increase the risk of lymphoma? Insights from genetic evidence.","authors":"Jing Liu, Jun Wang, Yuanyuan Zhang","doi":"10.1080/17474086.2025.2570329","DOIUrl":"https://doi.org/10.1080/17474086.2025.2570329","url":null,"abstract":"Background: Lymphoma poses a significant public health challenge with complex subtypes. While obesity and adipokines have been linked to lymphoma, causal relationships remain unclear. This study uses Mendelian randomization (MR) to systematically assess these associations.Research design and methods: Two-sample MR analyzed genetic data from genome-wide association studies to evaluate causal links between obesity, adipokines (adiponectin, leptin, resistin), and lymphoma subtypes (diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, Hodgkin lymphoma and other unspecified types of non-Hodgkin lymphoma). Primary analysis used inverse variance weighted (IVW), supported by MR-Egger, weighted median, and weighted mode methods. Sensitivity analyses (MR-Egger regression, Cochran's Q test, MR-PRESSO, leave-one-out) and linkage disequilibrium score regression (LDSC) ensured robustness.Results: IVW revealed obesity positively associated with follicular lymphoma (OR = 1.352, 95%CI: 1.095-1.670, p = 0.005) and other unspecified types of non-Hodgkin lymphoma (OR = 1.297, 95%CI: 1.050-1.603, p = 0.016). No significant links were found between adipokines and lymphoma. Sensitivity analyses confirmed no heterogeneity or pleiotropy.Conclusions: Obesity may independently increase lymphoma risk, unrelated to adipokines. These findings highlight new risk factors, urging further research into pathological mechanisms and biomarkers.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145285794","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mechanism regulation of endoplasmic reticulum stress in multiple myeloma cells: modulation of the UPR, UPS, autophagy, HSPs, and potential therapeutic targets. 多发性骨髓瘤细胞内质网应激的调节机制：UPR、UPS、自噬、热休克蛋白和潜在治疗靶点的调节。

IF 2.1 4区医学

Expert Review of Hematology Pub Date : 2025-10-11 DOI: 10.1080/17474086.2025.2574713

Ruth Angélica Lezama, Alexis Gudiño García, Karla López Ramírez, Jorge Vela Ojeda, Elba Reyes Maldonado, Zitlal-Lin Victoria-Avila

{"title":"Mechanism regulation of endoplasmic reticulum stress in multiple myeloma cells: modulation of the UPR, UPS, autophagy, HSPs, and potential therapeutic targets.","authors":"Ruth Angélica Lezama, Alexis Gudiño García, Karla López Ramírez, Jorge Vela Ojeda, Elba Reyes Maldonado, Zitlal-Lin Victoria-Avila","doi":"10.1080/17474086.2025.2574713","DOIUrl":"https://doi.org/10.1080/17474086.2025.2574713","url":null,"abstract":"Introduction: Multiple myeloma (MM) progression results from complex interactions between tumor cells, cytokines, and the tumor microenvironment (TME). MM cells constantly produce paraprotein, causing endoplasmic reticulum stress (ERS). Cell survival relies on adaptive mechanisms such as the unfolded protein response (UPR), autophagy, and heat shock proteins (HSPs). This review emphasizes the role of ERS in MM cell survival and explores emerging therapeutic strategies targeting ERS-related pathways, including chemical agents, natural compounds, and inhibitors of autophagy, HSPs, or the proteasome.Areas covered: ERS in MM cells is a process that must be understood to provide a more complete understanding of this disease. This review analyzed review articles on ERS in normal cells, cancer, and MM, ERS proteins as drug targets in MM, and reports of scientific papers on ERS and MM. The articles were selected from PubMed from 1998 to 2025. and the Global Cancer Observatory website was also consulted.Expert opinion: The primary mechanisms regulating ERS are overexpressed in MM cells, and their inhibition can lead to apoptosis, making them potential therapeutic targets. ERS and autophagy are associated with changes in the immune cells of the TME, acting as an immune-evasive mechanism that promotes malignant progression.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145274275","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Analysis of diagnostic value of lncRNA HCP5 in immune thrombocytopenia and its predictive value for disease progression. lncRNA HCP5在免疫性血小板减少症中的诊断价值及其对疾病进展的预测价值分析。

IF 2.1 4区医学

Expert Review of Hematology Pub Date : 2025-10-10 DOI: 10.1080/17474086.2025.2570330

Yunqi Liu, Dingqiong Wang, Hong Zhang, Jinfeng Du, Yi Liao

{"title":"Analysis of diagnostic value of lncRNA HCP5 in immune thrombocytopenia and its predictive value for disease progression.","authors":"Yunqi Liu, Dingqiong Wang, Hong Zhang, Jinfeng Du, Yi Liao","doi":"10.1080/17474086.2025.2570330","DOIUrl":"https://doi.org/10.1080/17474086.2025.2570330","url":null,"abstract":"Background: Studies showed that lncRNA HCP5 was associated with a variety of autoimmune diseases. This study evaluated the diagnostic potential of lncRNA HCP5 for immune thrombocytopenia (ITP) and its prognostic value in predicting disease progression, offering clinical application insights.Research design and methods: This study analyzed 40 ITP patients and 40 controls. qRT-PCR measured lncRNA HCP5 expression, while flow cytometry quantified Th17/Treg percentages. Pearson correlation assessed HCP5-clinical feature relationships. ROC analysis determined diagnostic potential, and Kaplan-Meier/Cox regression evaluated prognostic significance.Results: ITP patients showed decreased platelet counts, Treg percentages, and lncRNA HCP5 levels, but increased Th17%s versus controls. LncRNA HCP5 showed positive correlation with platelets/Tregs but negative with Th17 cells, and was associated with ITP bleeding severity. With a cutoff of 0.825, lncRNA HCP5 had an AUC of 0.979 for ITP diagnosis, sensitivity of 0.900, and specificity of 0.925. Kaplan-Meier analysis showed increased 1-year recurrence with low HCP5 expression, and Cox regression confirmed it as a poor prognostic factor.Conclusions: LncRNA HCP5 expression correlated significantly with Treg cell percentage, Th17 cell percentage, and the degree of bleeding in ITP patients. LncRNA HCP5 has high diagnostic and prognostic value for ITP.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145274259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Current trends and future artificial intelligence applications in transfusion medicine: a bibliometric analysis. 当前趋势和未来人工智能在输血医学中的应用：文献计量学分析。

IF 2.1 4区医学

Expert Review of Hematology Pub Date : 2025-10-10 DOI: 10.1080/17474086.2025.2570336

Tinghua Zhang, Youyuan Hu, Chengdong Tang, Chunyan Yang

引用次数: 0

Masked polycythemia vera: diagnostic challenges and clinical implications. 隐蔽性真性红细胞增多症：诊断挑战和临床意义。

IF 2.1 4区医学

Expert Review of Hematology Pub Date : 2025-10-09 DOI: 10.1080/17474086.2025.2570337

Zeynep Aslı Durak, Zehra Demirci, Ahmet Emre Eşkazan

引用次数: 0

Stem cell boost for immune effector cell associated hematotoxicity in multiple myeloma: minimizing long-term complications and expanding post CAR T-cell therapy relapse options. 干细胞增强免疫效应细胞相关的多发性骨髓瘤血液毒性：减少长期并发症和扩大CAR -t细胞治疗后复发的选择

IF 2.1 4区医学

Expert Review of Hematology Pub Date : 2025-10-09 DOI: 10.1080/17474086.2025.2570335

Meera Mohan, Carolina Schinke

{"title":"Stem cell boost for immune effector cell associated hematotoxicity in multiple myeloma: minimizing long-term complications and expanding post CAR T-cell therapy relapse options.","authors":"Meera Mohan, Carolina Schinke","doi":"10.1080/17474086.2025.2570335","DOIUrl":"10.1080/17474086.2025.2570335","url":null,"abstract":"Introduction: Cytopenia is one of the most common adverse events after BCMA chimeric antigen receptor (CAR) T cell therapy in the treatment of relapsed multiple myeloma (MM). The term Immune Effector Cell Associated Hematotoxicity (ICAHT) was coined to describe the unique hematological toxicities following novel CAR T cell therapies. The management of prolonged ICAHT ( > 30 days) is quite challenging, and patients have high incidences of infections, require prolonged transfusion support and have an increased non-relapse mortality. Stem cell boost (SCB) leads to prompt and durable count recovery and can minimize long-term complications while enabling therapeutic options in the post CAR T-cell therapy relapse setting.Areas covered: Herein we review current data on ICAHT, determine how SCB can lead to improved outcomes, and offer a view on future applications of SCB. The database 'pubmed' was searched for the terms 'CAR-T,' 'ICAHT', and 'Stem Cell', and results as well as selected citations were used for the present study.Expert opinion: SCB for prolonged ICAHT improves morbidity and potentially mortality. Future use of SCB will depend on the long-term outcomes of CAR-T cell therapy in earlier treatment lines. For patients with high likelihood of ICAHT, prophylactive stem cell collection should be considered.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"1-7"},"PeriodicalIF":2.1,"publicationDate":"2025-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145228428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Real-world analysis and cost-effectiveness of iron chelation therapy adherence in transfusion-dependent thalassemia. 输血依赖性地中海贫血患者铁螯合治疗依从性的现实世界分析和成本效益。

IF 2.1 4区医学

Expert Review of Hematology Pub Date : 2025-10-07 DOI: 10.1080/17474086.2025.2570338

Wan Jin Lee, Nurul Ain Mohd Tahir, Farida Islahudin, Shu Chuen Li

{"title":"Real-world analysis and cost-effectiveness of iron chelation therapy adherence in transfusion-dependent thalassemia.","authors":"Wan Jin Lee, Nurul Ain Mohd Tahir, Farida Islahudin, Shu Chuen Li","doi":"10.1080/17474086.2025.2570338","DOIUrl":"10.1080/17474086.2025.2570338","url":null,"abstract":"Background: Adherence to iron chelation therapy (ICT) is essential for preventing iron overload complications and optimizing health outcomes in transfusion-dependent thalassemia (TDT) patients. This study evaluates the cost-effectiveness of ICT adherence in Malaysia.Research design and methods: A cross-sectional analysis was conducted at a tertiary hospital. Adherence was measured using the Malaysia Medication Adherence Assessment Tool, and health utility values were assessed with SF-6D. Based on the societal perspective, costs and quality-adjusted life years (QALYs) were compared between adherent and non-adherent patients, with incremental cost-effectiveness ratio (ICER) calculations and sensitivity analyses.Results: One hundred and sixty-two adult TDT patients were recruited. Adherent patients (n = 76) achieved higher QALYs (0.783 vs. 0.733) but incurred slightly higher annual costs ($7,773.26 vs. $7,643.33). The ICER of $2,598.90 per QALY remained below Malaysia's willingness-to-pay threshold ($5,441.16), confirming cost-effectiveness. Sensitivity analyses indicated that cost variations significantly influenced the ICER, while utility values had minimal impact.Conclusions: The findings underscore the economic and clinical benefits of ICT adherence, advocating for targeted strategies to enhance compliance. Future research should explore long-term cost implications and intervention strategies to improve adherence, ensuring sustainable thalassemia management.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"1-8"},"PeriodicalIF":2.1,"publicationDate":"2025-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145231879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Novel therapeutics for immune thrombocytopenia: an evolving treatment landscape. 免疫性血小板减少症的新疗法：不断发展的治疗前景。

IF 2.1 4区医学

Expert Review of Hematology Pub Date : 2025-10-04 DOI: 10.1080/17474086.2025.2570332

Kun Huang

{"title":"Novel therapeutics for immune thrombocytopenia: an evolving treatment landscape.","authors":"Kun Huang","doi":"10.1080/17474086.2025.2570332","DOIUrl":"10.1080/17474086.2025.2570332","url":null,"abstract":"Introduction: Immune thrombocytopenia (ITP) is an autoimmune-bleeding disorder; its management is shifting from empiricimmunosuppression and splenectomy to targeted, pathway-specific drugs that raise platelet counts with fewer long-term toxicities.Areas covered: This review critically appraises evidence behind six mechanistic drug classes poised to reshape ITP care: thrombopoietin receptor agonists, spleen tyrosine kinase inhibitors, reversible Brutontyrosine kinase inhibitors, neonatal Fc-receptor antagonists, proximal complementblockers, and plasma-cell or BAFF-directed therapies. We interrogated PubMed, ClinicalTrials.gov, and hematology-conference abstracts (January 2010-May2025), retrieving synthesizing phase 2-3 trials and key observational studies. Throughout, we contrast these agents with steroids, intravenous immunoglobulin, and rituximab, highlighting shared immunomodulatory nodes and unique points of divergence that may inform rational sequencing or combination.Expert opinion: Mechanism-focused agents already enable steroid-sparing outpatient regimens and personalized care, yet durable remission and predictive biomarkers remain elusive. FcRn and reversible BTK inhibitors are closest to regulatory approval; complement blockade delivers24-hour platelet rescue, while plasma-cell or BAFF inhibition may consolidate sustained disease control. Research priorities include biomarker-guided pathway selection, optimal positioning with thrombopoietin receptor agonists, long-termpharmacovigilance, and cost-effectiveness analyses to ensure equitable global access.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"1-15"},"PeriodicalIF":2.1,"publicationDate":"2025-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145206003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0